Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Status Active, not recruiting

Clinical Trial Summary

This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C). The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses). Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening. Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.

Clinical Trial Description

This study will have three parts. Part A of the study is designed to evaluate the incidence of febrile neutropenia, efficacy, and dose intensity in participants with advanced stage classical Hodgkin lymphoma (cHL) receiving granulocyte colony stimulating factor primary prophylaxis (G-PP) administration during treatment with frontline A+AVD. In Part A, participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment. Participants will be treated using institutional standard of care practices for the majority of treatment decisions. Part B is designed to evaluate the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) as frontline treatment in participants with advanced cHL. In Part B, participants will be given AN+AD combination for 6 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage II with bulky mediastinal disease and Stage III or IV cHL. Part C is designed to evaluate AN+AD as frontline treatment in participants with early stage cHL. In Part C, participants will be given AN+AD combination for 4 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage I or II cHL with non-bulky mediastinal disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03646123
Study type	Interventional
Source	Seagen Inc.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 28, 2019
Completion date	June 7, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05400122` - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer	Phase 1
Completed	`NCT01947140` - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies	Phase 1/Phase 2
Recruiting	`NCT05019976` - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma	N/A
Active, not recruiting	`NCT03617666` - Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study	Phase 2
Completed	`NCT04666025` - SARS-CoV-2 Donor-Recipient Immunity Transfer
Recruiting	`NCT02507479` - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies	Phase 2
Active, not recruiting	`NCT02191930` - Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma	Phase 2
Completed	`NCT01943682` - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma	Phase 1
Completed	`NCT01393106` - Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Terminated	`NCT00992030` - R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma	Phase 3
Terminated	`NCT00722865` - Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma	Phase 2
Unknown status	`NCT00598624` - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)	Phase 2
Completed	`NCT03242902` - To Decrease Fatigue With Light Therapy	Phase 3
Active, not recruiting	`NCT05205512` - Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial	N/A
Recruiting	`NCT03681561` - Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma	Phase 1/Phase 2
Recruiting	`NCT03250962` - SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma	Phase 2
Recruiting	`NCT04510610` - Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma	Phase 2/Phase 3
Completed	`NCT06295211` - Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Active, not recruiting	`NCT02256137` - A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
Completed	`NCT02432235` - Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma	Phase 1